No abstract

Lung cancer is the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase ( ALK ) gene rearrangements constitutes 3-5%. Crizotinib was approved for the first-line therapy of advanced ALK-positive NSCLC patients. We present a female patient with advanced ALK-positive NSCLC who was kept on crizotinib as first-line therapy and showed progression-free survival (PFS) of 48 months despite the data suggesting that the majority of patients on crizotinib show relapse within 1 year. Further studies should focus on the molecular and biological factors and the possible effect of the long-term use of this drug.

Aim: This work aimed to study the efficacy and safety of preoperative intravenous tranexamic acid to reduce blood loss during and after elective lower-segment cesarean delivery. Materials and Methods: A double-blind, randomized placebo-controlled study was undertaken of women undergoing elective lower-segment cesarean delivery of a full-term singleton pregnancy at a center in tertiary referral hospital , Egypt, between December, 2019 and March, 2020. Patients were randomly assigned (1:1) using computer-generated random numbers to receive either 1 g tranexamic acid(TXA) or 5% glucose 15 minutes before surgery. Preoperative and postoperative complete blood count, hematocrit values, and maternal weight were used to calculate the estimated blood loss (EBL) during cesarean section, which was the primary outcome. Analyses included women who received their assigned treatment, whose surgery was 90 minutes or less, and who completed follow-up. Results: Eighty women in each group.There was no statistical difference found between women subjected to TXA and those subjected to placebo regarding maternal age, weight, gestational age or mode of previous delivery. Mean EBL was significantly higher in the placebo group (896.81 ± 519.6mL mL) than in the tranexamic acid group (583.23 ± 379.62mL; P < 0.001). Conclusion:Preoperative administration of tranexamic acid safely reduces blood loss during elective lower-segment cesarean delivery.

To correlate histomorphology of the placenta with Doppler studies of uterine and umbilical arteries. A comparative observational study conducted on 75 pregnant women divided into 2 groups: Group 1 included 25 women with appropriate for gestational age fetuses. Group 2 included 50 women with FGR. Uterine and umbilical artery Doppler, study of placental pathology and immunohistochemistry of placental villous tissues were evaluated. There was a significant difference between the two study groups regarding both abnormal uterine (0 vs. 58%) and umbilical artery (0 vs. 58%) Doppler (p \ 0.001). Syncytial knots [ 30% (44 vs. 60%), fibrinoid necrosis [ 5% (8 vs. 46.7%), placental infarction [ 5% (0 vs. 15%), perivillous fibrinoid deposition [ 5% (1.8 vs. 16.7%) (p \ 0.001) but not calcifications (56 vs. 60%, p = 0.121) were significantly higher in FGR placentas. A statistically significant (p \ 0.001) increase in the expression of VEGF in FGR placentas when compared with normal placentas. Abnormal uterine artery but not umbilical artery Doppler was significantly associated with abnormal placental pathology. Women with both abnormal uterine and umbilical artery Doppler velocimetries were delivered earlier and their babies had lower mean birth and placental weight (p \ 0.001). Incidence of abnormal placental pathology was significantly higher in this specific group of FGR pregnancies (p \ 0.001). There is high association between abnormal uterine and umbilical artery Doppler and placental pathology in FGR associated pregnancies.Trial Registration NCT03081754.

In the article titled "Efficacy and Safety of Preoperative Intravenous Tranexamic Acid to Reduce Blood Loss During and After Elective Lower-Segment Cesarean Delivery", published on pages 177-181, Issue 2, Volume 11 of Evidence Based Women's Health Journal. This article has been retracted from our journal.